Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Xiaoli S. Glasgow"'
Autor:
Candice Bailey‐Smith, Inga Bodrug, Monika Martinho, Amy Cheng, Lally Mekokishvili, Marian Iwamoto, Diana Montgomery, Azher Hussain, Peter M. Shaw, Vanessa Levine, Sauzanne Khalilieh, Xiaoli S. Glasgow
Publikováno v:
British Journal of Clinical Pharmacology. 84:2292-2302
Aims Tildrakizumab, an interleukin (IL)-23 inhibitor, is indicated for the treatment of moderate to severe chronic plaque psoriasis. Although tildrakizumab is not metabolized by, and does not alter, cytochrome P450 (CYP) expression in vitro, clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09b599d9985ea6350f998650ccd3ca9c
https://doi.org/10.1111/bcp.13670
https://doi.org/10.1111/bcp.13670
Autor:
Carol Addy, Ashley Martucci, Marleen Depré, J. N. de Hoon, Joanna Z. Peng, John A. Wagner, Amy O. Johnson-Levonas, I.N. Gendrano, Rajesh Krishna, S. Aubrey Stoch, Wouter Haazen, Martine Robberechts, Xiaoli S. Glasgow, Daniel Tatosian
Publikováno v:
Journal of Clinical Pharmacology
The pharmacokinetics (PK), and pharmacodynamics (PD) of omarigliptin, a novel once-weekly DPP-4 inhibitor, were assessed following single and multiple doses in healthy subjects. Absorption was rapid and food did not influence single dose PK. Accumula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eac3d7bfddd47c77aeb8b72ff77df0be
https://doi.org/10.1002/jcph.773
https://doi.org/10.1002/jcph.773
Autor:
Laura George, Bruce DeGroot, Dennis Swearingen, Xiaoli S. Glasgow, Daniel Tatosian, Eunkyung Kauh, Amy O. Johnson-Levonas, Katherine Dunnington, Nadia Cardillo Marricco, I.N. Gendrano
Publikováno v:
Clinical Pharmacology in Drug Development. 5:383-392
Omarigliptin is a dipeptidyl peptidase-4 inhibitor being developed as a once-weekly treatment for type 2 diabetes. This double-blind, double-dummy, randomized, 3-period balanced crossover study definitively evaluated the effects of a supratherapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::040d22f4d04507ecccea76b363987c1d
https://doi.org/10.1002/cpdd.260
https://doi.org/10.1002/cpdd.260
Autor:
Eunkyung Kauh, John A. Wagner, Daniel Tatosian, Carol Addy, Christine McCrary Sisk, I.N. Gendrano, S. Aubrey Stoch, Xiaoli S. Glasgow
Publikováno v:
Clinical Pharmacology in Drug Development. 5:374-382
Omarigliptin is being developed as a potent, once-weekly, oral dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. This double-blind, randomized, placebo-controlled study evaluated the effects of age, sex, and obesity on the pharma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::540558b2dd554ed4144919bf9192a1bf
https://doi.org/10.1002/cpdd.255
https://doi.org/10.1002/cpdd.255
Autor:
Carol Addy, Catherine Z. Matthews, I.N. Gendrano, Eunkyung Kauh, John A. Wagner, Diana Selverian, Ashley Martucci, S. Aubrey Stoch, Xiaoli S. Glasgow, Marie Gutierrez, Amy O. Johnson-Levonas, Daniel Tatosian
Publikováno v:
Clinical Therapeutics. 38:516-530
Purpose Omarigliptin (MK-3102) is a potent, oral, long-acting dipeptidyl peptidase (DPP)-4 inhibitor approved in Japan and in global development as a once-weekly treatment for type 2 diabetes mellitus (T2DM). The aim of this study was to investigate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::629fe6885c46fa0333084908eab7174e
https://doi.org/10.1016/j.clinthera.2015.12.020
https://doi.org/10.1016/j.clinthera.2015.12.020
Autor:
Sauzanne, Khalilieh, Azher, Hussain, Diana, Montgomery, Vanessa, Levine, Peter M, Shaw, Inga, Bodrug, Lally, Mekokishvili, Candice, Bailey-Smith, Xiaoli S, Glasgow, Amy, Cheng, Monika, Martinho, Marian, Iwamoto
Publikováno v:
British journal of clinical pharmacology. 84(10)
AIMS: Tildrakizumab, an interleukin (IL)‐23 inhibitor, is indicated for the treatment of moderate to severe chronic plaque psoriasis. Although tildrakizumab is not metabolized by, and does not alter, cytochrome P450 (CYP) expression in vitro, clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d7c87a599eec9a06cdec9a03804bc633
https://pubmed.ncbi.nlm.nih.gov/29926968
https://pubmed.ncbi.nlm.nih.gov/29926968
Autor:
Carol, Addy, Daniel A, Tatosian, Xiaoli S, Glasgow, Isaias Noel, Gendrano, Christine McCrary, Sisk, Eunkyung A, Kauh, S Aubrey, Stoch, John A, Wagner
Publikováno v:
Clinical pharmacology in drug development. 5(5)
Omarigliptin is being developed as a potent, once-weekly, oral dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. This double-blind, randomized, placebo-controlled study evaluated the effects of age, sex, and obesity on the pharma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::52cf1306b25519020b1cb704d6d33339
https://pubmed.ncbi.nlm.nih.gov/27627193
https://pubmed.ncbi.nlm.nih.gov/27627193